Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid
Eisen, Damon P., Corey, G. Ralph, McBryde, Emma S., Fowler, Vance G., Miro, Jose M., Cabell, Chris H., Street, Alan C., Paiva, Marcelo Goulart, Ionac, Adina, Tan, Ru-San, Tribouilloy, Christophe, Pachirat, Orathai, Jones, Sandra Braun, Chipigina, Natalia, Naber, Christoph, Pan, Angelo, Ravasio, Veronica, Gattringer, Rainer, Chu, Vivian H., and Bayer, Arnold S. (2009) Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. Journal of Infection, 58 (5). pp. 332-338.
PDF (Published Version)
- Published Version
Restricted to Repository staff only |
Abstract
Objectives: To assess the influence of acetyl-salicylic acid (ASA) on clinical outcomes in Staphylococcus aureus infective endocarditis (SA-IE).
Methods: The International Collaboration on Endocarditis e Prospective Cohort Study database was used in this observational study. Multivariable analysis of the SA-IE cohort compared outcomes in patients with and without ASA use, adjusting for other predictive variables, including: age, diabetes, hemodialysis, cancer, pacemaker, intracardiac defibrillator and methicillin resistance.
Results: Data were analysed from 670 patients, 132 of whom were taking ASA at the time of SAIE diagnosis. On multivariable analysis, ASA usage was associated with a significantly decreased overall rate of acute valve replacement surgery (OR 0.58 [95% CI 0.35e0.97]; p < 0.04), particularly where valvular regurgitation, congestive heart failure or periannular abscess was the indication for such surgery (OR 0.46 [0.25e0.86]; p < 0.02). There was no reduction in the overall rates of clinically apparent embolism with prior ASA usage, and no increase in hemorrhagic strokes in ASA-treated patients.
Conclusions: In this multinational prospective observational cohort, recent ASA usage was associated with a reduced occurrence of acute valve replacement surgery in SA-IE patients. Future investigations should focus on ASA's prophylactic and therapeutic use in high-risk and newly diagnosed patients with SA bacteremia and SA-IE, respectively.